Results 121 to 130 of about 25,852 (233)

Dual Antiplatelet Therapy in Acute Branch Atheromatous Disease (BAD)‐Related Stroke: A Multicenter Propensity‐Matched Cohort Analysis

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 7, July 2026.
The study aimed to compare the clinical outcomes of dual antiplatelet therapy (DAPT) vs. single antiplatelet therapy (SAPT) in branch atheromatous disease (BAD)‐related stroke. DAPT was safe but not statistically superior to SAPT for excellent functional outcome; however, its numerical trend toward benefit warrants further investigation.
Haizhou Hu   +10 more
wiley   +1 more source

Population Pharmacokinetics of Ticagrelor during Veno‐Arterial ECMO in Acute Coronary Syndrome: Model‐Informed Dosing Simulations

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 193-202, July 2026.
Although patients with acute coronary syndrome supported by veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO) have a high risk of thrombosis and bleeding, antiplatelet pharmacology in this setting is not well defined. This prospective observational study investigated the population pharmacokinetics of ticagrelor and its active metabolite AR ...
Soyoung Kang   +9 more
wiley   +1 more source

Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).

open access: yesPLoS ONE, 2016
Early stent thrombosis (EST) (≤ 30 days after stent implantation) is a relatively rare but deleterious complication of percutaneous coronary intervention (PCI). Administration of newer P2Y12 inhibitors (prasugrel and ticagrelor) combined with aspirin has
Elad Asher   +12 more
doaj   +1 more source

Quality of hospital medicine care in Veterans Affairs hospitals versus non‐Veterans Affairs hospitals: A systematic review of comparative studies

open access: yesJournal of Hospital Medicine, Volume 21, Issue 7, Page 792-800, July 2026.
Abstract Background The Veterans Health Administration (VA) cares for more than one million hospitalized Veterans each year. There is limited knowledge on how hospital medicine care in VA facilities compares with non‐VA hospitals in terms of the Institute of Medicine domains of healthcare access, patient experience, quality, clinical outcomes, and cost.
Paul G. Shekelle   +4 more
wiley   +1 more source

Stage‐Associated Microglial Subpopulations and Dynamics in Vascular Pathogenesis of Oxygen‐Induced Retinopathy

open access: yesCell Proliferation, Volume 59, Issue 7, July 2026.
In the oxygen‐induced retinopathy (OIR) mouse model, two distinct microglial subpopulations play opposing roles: highly glycolytic microglia (HGM) promote neovascular formation via Pkm2, while Mrc1/CD206‐positive phagocytosis‐associated microglia (PAM) facilitate its regression.
Yuan Ma   +20 more
wiley   +1 more source

Beyond Hemostasis: Platelet Biomarkers and Vascular‐Immune Crosstalk in Dengue

open access: yesThe FASEB Journal, Volume 40, Issue 12, 30 June 2026.
Several biomarkers are associated with platelet activation during dengue virus (DENV) infection. These include serum markers (AST, ALT, ferritin), platelet surface or secreted molecules (P‐selectin, PF4, RANTES, VEGF‐A, CD40L, TREM‐1, TLT‐1), immune and endothelial markers (TREM‐1, Ang‐1, Ang‐2), and viral components such as DENV EIII.
Amanda Beatriz Adriano da Silva‐Alencar   +6 more
wiley   +1 more source

Association of perioperative P2Y12 inhibitor administration with outcomes for tandem occlusion: RESCUE AT-LVO sub-study

open access: yesFrontiers in Neurology
BackgroundWe aimed to clarify the association between intraoperative P2Y12 inhibitor administration during EVT and clinical outcomes in patients with anterior circulation TO stroke.MethodsAmong consecutive patients with acute ischemic stroke (AIS ...
Takeshi Yoshimoto   +31 more
doaj   +1 more source

Response variability to P2Y12 receptor inhibitors: expectations and reality.

open access: yesJACC. Cardiovascular interventions, 2013
P2Y12 inhibitors are widely used in patients with acute coronary syndromes and in the secondary prevention of thrombotic events in vascular diseases. Within the past few years, several pharmacological, genetic, and clinical limitations of the second-generation thienopyridine clopidogrel have raised major concerns. High on-treatment platelet reactivity,
Siller-Matula, Jolanta M   +6 more
openaire   +2 more sources

Die Rolle des P2Y12-Rezeptors in adipozytärem Gewebe [PDF]

open access: yes
In dieser Studie konnte gezeigt werden, dass der P2Y12-Rezeptor sowohl in ausdifferenzierten murinen als auch in humanen braunen und weißen Adipozyten exprimiert wird. Die Expression ließ sich sowohl durch Ernährung als auch durch die Umgebungstemperatur
Bienert, Simon
core  

Early treatment with inhibitors of P2Y12 receptor in patients with ST-segment elevation myocardial infarction — 2023 ESC recommendations and scientific evidence. Is clinical evidence sufficient to suggest a move towards precision medicine? The ELECTRA-SIRIO 2 investigators’ viewpoint

open access: yesCardiology Journal
The 2023 ESC guidelines changed previously recommended a strategy of early treatment in patients with STEMI. Pre-treatment with a P2Y12 receptor inhibitor may be considered in patients undergoing a primary PCI strategy (Class IIb, Level of evidence B ...
Jacek Kubica   +31 more
doaj   +1 more source

Home - About - Disclaimer - Privacy